%0 Journal Article
%A Helen Dakin
%A Ines Rombach
%A Melina Dritsaki
%A Alastair Gray
%A Catherine Ball
%A Sarah E. Lamb
%A Jagdeep Nanchahal
%T Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease
%D 2022
%J Bone & Joint Open
%P 898-906
%V 3
%N 11
%R 10.1302/2633-1462.311.BJO-2022-0103.R2
%U https://doi.org/10.1302/2633-1462.311.BJO-2022-0103.R2
%K Adalimumab,Anti-tumour necrosis factor,Cost-effectiveness analysis,Economic evaluation,Dupuytren’s disease,Palmar fibromatosis,Simulation model,Randomized controlled trial,randomized controlled trials,EQ-5D-5L,flexion deformities,radiotherapy,steroid injections,linear regression models,percutaneous needle fasciotomies,sensitivity analysis